ReviewFrontiers in immunology2014
Immunoglobulin replacement therapy in secondary hypogammaglobulinemia.
Review in Frontiers in immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 116 citations in OpenAlex.
- Population Pharmacokinetics and Pharmacodynamics of Immunoglobulins: A Systematic Review.Clinical pharmacokinetics · 2026Pooled it
- Pooled it
- Late-Onset Neutropenia and Hypogammaglobulinemia After Dose-Adjusted R-EPOCH in Unfavorable Diffuse Large B-Cell Lymphoma.Life (Basel, Switzerland) · 2026Article
- Italian recommendations for the diagnosis and treatment of myasthenia gravis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Pretreatment immunoglobulin profiles and survival outcomes in hematologic malignancies and autoimmune cytopenias: a comparative cohort analysis.BMC immunology · 2026Article
- The Cross-Knit Between Immune Cells and Thyroid Function in Autoimmune Thyroid Disorders: What We Can Learn from Inborn Errors of Immunity.Children (Basel, Switzerland) · 2026Review
- Quality improvement project - Implementation of subcutaneous immunoglobulin in patients with haematological disorders and secondary immunodeficiency.Therapeutic advances in hematology · 2026Article
- Article
- Study protocol for developing a patient-reported outcome measure for infection screening in hematological patients with secondary immunodeficiency.BMC cancer · 2025Article
- The Rehabilitation of a Patient with Acute Transverse Myelitis After HPV Vaccination-A Case Report.Diseases (Basel, Switzerland) · 2025Article
- Real-world effectiveness of immunoglobulin replacement for hypogammaglobulinemia and infections in multiple myeloma.Blood advances · 2025Article
- [Clinical study on intravenous human immunoglobulin (pH4) for hypogammaglobulinemia and infection risk following CD20 monoclonal antibody therapy in patients with B-cell non-Hodgkin lymphoma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Inborn errors of immunity underlie clonal T cell expansions in large granular lymphocyte leukemia.The Journal of clinical investigation · 2025Article
- Respiratory Burden in Hematology-Related Bronchiectasis: Clinical Characteristics and Treatable Traits.Respiration; international review of thoracic diseases · 2025Article
- Secondary Immunodeficiency and Non-cystic Fibrosis Bronchiectasis.Tuberculosis and respiratory diseases · 2024Article
- IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence.Blood advances · 2024Article
- Infections associated with CAR-T cell therapy in patients with relapsed refractory multiple myeloma: Risks and prevention strategies.Cancer medicine · 2024Review
- Effectiveness of immunoglobulin replacement therapy in preventing infections in patients with chronic obstructive pulmonary disease: a systematic review.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2024Article
- A survival case of visceral disseminated varicella zoster virus infection in a patient with systemic lupus erythematosus.BMC nephrology · 2023Article
- Patients with indolent lymphomas are at high risk of infections: experience from a German outpatient clinic.BMC immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulin (Ig) replacement therapy dramatically changed the clinical course of primary hypogammaglobulinemias, significantly reducing the incidence of infectious events. Over the last two decades its use has been extended to secondary antibody deficiencies, particularly those related to hematological disorders as lymphoproliferative diseases (LPDs) and multiple myeloma. In these malignancies, hypogammaglobulinemia can be an intrinsic aspect of the disease or follow chemo-immunotherapy regimens, including anti-CD20 treatment. Other than in LPDs the broadening use of immunotherapy (e.g., rituximab) and immune-suppressive therapy (steroids, sulfasalazine, and mycophenolate mofetil) has extended the occurrence of iatrogenic hypogammaglobulinemia. In particular, in both autoimmune diseases and solid organ transplantation Ig replacement therapy has been shown to reduce the rate of infectious events. Here, we review the existing literature about Ig replacement therapy in secondary hypogammaglobulinemia, with special regard for subcutaneous administration route, a safe, effective, and well-tolerated treatment approach, currently well established in primary immunodeficiencies and secondary hypogammaglobulinemias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.